ALPN-101

AbbVie beefs up the immunology pipeline, betting up to $865M on a PhII-ready drug — and fueling a biotech stock frenzy
Endpoints
Thu, 06/18/20 - 10:55 am
AbbVie
Mitchell Gold
Dendreon
ALPN-101
immunology
Alpine Immune Sciences
lupus